周四盘中，康希诺生物（06185.HK）股价大涨5.31%，投资者对公司最新发布的中期业绩报告反应积极。
根据康希诺生物公布的截至2025年6月30日止的中期业绩报告，公司亏损明显收窄。报告显示，公司股东应占亏损为1348.5万元人民币，相比去年同期的2.25亿元人民币亏损，亏损幅度大幅减少。每股亏损为0.05元人民币，公司决定不派息。
值得注意的是，康希诺生物2025年上半年收入录得3.74亿元人民币，同比增长31.1%。这一增长反映了公司业务的积极发展态势。尽管公司仍处于亏损状态，但亏损的显著收窄和收入的强劲增长，显示出公司经营状况正在持续改善，这可能是推动股价上涨的主要因素。投资者似乎对公司未来的发展前景持乐观态度，推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.